Using a blood test to predict hepatitis B long-term outcomes
Part of Cancer, Infections clinical trials.
This study looks at hepatitis B “pgRNA” in blood to see if it can predict long-term outcomes in people with chronic hepatitis B who are treated with antiviral medicines. It may help doctors better forecast risk and guide follow-up over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic hepatitis B (hepatitis B surface antigen positive for at least 6 months, or related liver changes within the past year).
- You are between 18 and 80 years old.
- You are starting or already began first-line hepatitis B treatment (interferon and/or antiviral pills, alone or in combination).
- Your clinician has decided you need antiviral therapy based on your condition.
- You can read and sign the informed consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study compares two ways of giving treatment for chronic hepatitis B: continuous antiviral therapy versus pulsed treatment. It may help find a schedule that works well and is tolerable for people with hepatitis B.
This study looks at how to best use existing hepatitis B “nucleotide-analog” tablets in everyday care. It may help tailor when to start, and whether to continue or adjust treatment, based on your test results.
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
This study looks at a new way to detect the hepatitis B virus in the blood, even after standard tests say it's gone. It may help people who have stopped treatment and want to see if the virus comes back.
This study looks at genetic factors that may help people with chronic hepatitis B achieve a clinical cure when treated with long-acting interferon. It aims to find out why some patients respond better than others.
This study looks at whether non-invasive tests can tell if liver damage is reversing in people with hepatitis B who have been on antiviral therapy for at least a year. It aims to help avoid repeated liver biopsies.
Hear when a new HBV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.